Stem Cell Superpowers Unite to Unleash Global iPSC Therapies

VANCOUVER, BC and TOKYO – March 03, 2026 – In a move set to accelerate the future of medicine, two of the world's leading regenerative medicine bodies have joined forces. The International Society for Cell & Gene Therapy (ISCT) and the Japanese Society for Regenerative Medicine (JSRM) today announced a landmark 5-year strategic partnership aimed at transforming induced Pluripotent Stem Cell (iPSC) research from a promising science into accessible, life-saving therapies for patients across the globe.

The ISCT–JSRM Joint Strategic Collaboration on Clinical iPSCs will officially launch in Kobe, Japan, this month. Its mission is to dismantle the complex scientific, regulatory, and commercial bottlenecks that currently hinder the progress of iPSC-based treatments, establishing a global infrastructure for their safe and effective deployment.

Japan's Blueprint for a Regenerative Future

The collaboration's kickoff in Kobe is deeply symbolic. The city is hailed as the birthplace of human iPSC transplantation, where the world's first clinical application of iPSC-derived cells took place in 2014. That pioneering study, led by Dr. Masayo Takahashi for age-related macular degeneration (AMD), provided the crucial proof-of-concept that has since fueled a wave of innovation, primarily within Japan.

Japan has cultivated a uniquely supportive ecosystem for regenerative medicine. Its Pharmaceuticals and Medical Devices Agency (PMDA) has established an expedited approval pathway, allowing promising therapies to reach patients faster. This forward-thinking regulation has recently led to recommendations for conditional marketing approval for the world's first iPSC-derived therapeutic products: Amchepry for Parkinson's disease and ReHeart for severe heart failure. This national success story forms the bedrock of the new global partnership.

"There are big challenges ahead," acknowledged Masayo Takahashi, MD, PhD, who now serves as the JSRM Chair for the joint collaboration. "By leveraging the networks and expertise of both ISCT and JSRM, however, we will create a meaningful global collaboration that will set a standard of knowledge, of approach, and of integration...so that patients not only in Japan, but across the globe, can benefit."

The Global Challenge: From Harmonization to Healing

While Japan has provided a blueprint, the path to global adoption is fractured. Developers of iPSC therapies currently face a patchwork of differing regulatory standards across key markets like the United States and Europe. Navigating the U.S. FDA's Regenerative Medicine Advanced Therapy (RMAT) designation or the European Medicines Agency's (EMA) framework for Advanced Therapy Medicinal Products (ATMPs) presents distinct and costly challenges, slowing down multinational clinical trials and hindering patient access.

This lack of harmony is a primary target for the new collaboration. Beyond regulatory differences, the field is grappling with universal technical hurdles. With over 115 clinical trials now underway globally for PSC-derived products, ensuring long-term safety, preventing tumor formation, and guaranteeing the genetic stability of cell lines are paramount. Furthermore, manufacturing these complex living medicines at scale remains a costly and labor-intensive process.

"This is a formative time for iPSCs. The first rigorous clinical trials are beginning to be reported, particularly in Japan," said George Muschler, MD, ISCT Chair for the joint collaboration. "Regulatory structures have been framed but need to be harmonized internationally. Automated platforms for high quality manufacturing for single individuals and large populations are coming online. Our ISCT-JSRM Collaboration is an essential forum...to distill opportunities into targeted, safe, effective, and accessible therapies."

Unlocking a Multi-Billion Dollar Market

The stakes are not just clinical; they are profoundly economic. The global iPSC market, valued at over $1.8 billion in 2024, is projected to surge to nearly $5 billion by 2034. This growth is fueled by the promise of treating chronic conditions in aging populations and the technology's application in drug discovery. Venture capital has taken notice, pouring over $3.4 billion into the sector since 2021, signaling strong investor confidence.

However, for iPSC therapies to achieve their full commercial potential, the path from lab to market must be de-risked. By creating clear, harmonized standards for safety, manufacturing, and clinical trial design, the ISCT-JSRM partnership aims to provide the predictability and stability that investors and pharmaceutical companies require. The collaboration will also tackle the critical issue of commercial viability, promoting sustainable reimbursement models through early engagement between developers and payors to ensure these potentially expensive treatments can become a viable option for healthcare systems.

A Five-Year Roadmap to a New Era of Medicine

The collaboration is not a mere forum for discussion but an outcomes-focused initiative with a detailed five-year plan. Annual events, alternating between ISCT and JSRM meetings, will track progress and set future goals. The agenda is ambitious, targeting seven key areas: advancing clinical translation, driving technological innovation with AI and automation, enabling regulatory innovation, harmonizing global standards, educating a new generation of experts, promoting commercial realization, and strengthening medical affairs to connect clinical evidence with policymakers.

"Alongside ISCT, we see the pathway ahead to fulfilling the promise of iPSCs at a global scale," said Kohji Nishida, MD, PhD, President of JSRM. "We are excited to work together on these key events, so that we can both bring our work to the global table, and also learn from others in the CGT space."

By uniting JSRM's pioneering clinical experience with ISCT's global network of over 4,500 experts across 60 countries, the initiative represents the most significant effort to date to build a cohesive, worldwide ecosystem for regenerative medicine.

"iPSCs provide a unique opportunity for the CGT field as research begins to mature into therapies," concluded Miguel Forte, MD, PhD, President of ISCT. "Together with our partners at JSRM, ISCT will leverage its global network to drive advancement from foundation to ecosystem, from region to globe. Success here will blaze a trail for other CGT platforms that are advancing at an accelerating pace."